Welcome to another episode of the Oncology Brothers podcast! In this episode, we dived into the recent FDA approval of Durvalumab combined with chemotherapy for resectable muscle-invasive bladder cancer, based on the NIAGARA trial.

Join us as we chat with Dr. Thomas Powles, a GU medical oncologist and the lead author of the NIAGARA trial. We discussed the study design, the significant improvements in overall survival, and the implications of this new treatment approach. Dr. Powles shared insights on the use of immunotherapy in the perioperative setting, the importance of pathological complete response, and the safety of combining Durvalumab with chemotherapy.

Key topics covered in this episode:
•⁠ ⁠Overview of the NIAGARA trial and its findings
•⁠ ⁠Comparison of Durvalumab and cisplatin-based chemotherapy outcomes
•⁠ ⁠The significance of event-free survival and overall survival rates
•⁠ ⁠Insights on managing side effects and treatment sequencing
•⁠ ⁠The evolving role of ctDNA in determining treatment strategies

YouTube: https://youtu.be/s_tXoX5yhV8

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠ Website: https://oncbrothers.com/

Tune in to learn how these advancements are changing the landscape of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology and FDA approvals!
#OncologyBrothers #BladderCancer #Dervalumab #FDAApproval #NiagaraTrial #Immunotherapy #CancerResearch #OncologyPodcast

101 - The Great Shart Hunt 10.29.20